Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice

Journal of Cellular Physiology

Volumn 229, Issue 9, 2014, Pages 1283-1291

  Strimpakos, Georgios ^a   Corbi, Nicoletta ^b   Pisani, Cinzia ^b   Di Certo, Maria Grazia ^a   Onori, Annalisa ^b   Luvisetto, Siro ^a   Severini, Cinzia ^a   Gabanella, Francesca ^a   Monaco, Lucia ^c   Mattei, Elisabetta ^a   Passananti, Claudio ^b  

^a CNR   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; JAZZ PROTEIN; PARVOVIRUS VECTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UTROPHIN; ZINC FINGER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION; GENE THERAPY; IN VIVO STUDY; INFLAMMATORY CELL; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SEROTYPE; SKELETAL MUSCLE; THERAPY EFFECT; UPREGULATION; VIRAL GENE THERAPY;

ACTINS; ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GENOTYPE; HUMANS; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NECROSIS; PHENOTYPE; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; RECOVERY OF FUNCTION; TIME FACTORS; TRANSCRIPTION FACTORS; UP-REGULATION; UTROPHIN; ZINC FINGERS;

EID: 84901227909     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24567     Document Type: Article

References (44)

1. Amenta AR, Creely HE, Mercado ML, Hagiwara H, McKechnie BA, Lechner BE, Rossi SG, Wang Q, Owens RT, Marrero E, Mei L, Hoch W, Young MF, McQuillan DJ, Rotundo RL, Fallon JR. 2012. Biglycan is an extracellular MuSK binding protein important for synapse stability. J Neurosci 32:2324-2334.
2. Basu U, Gyrd-Hansen M, Baby SM, Lozynska O, Krag TO, Jensen CJ, Frödin M, Khurana TS. 2007. Heregulin-induced epigenetic regulation of the utrophin-A promoter. FEBS Lett 581:4153-4158.
3. Beltran AS, Blancafort P. 2010. Remodeling genomes with artificial transcription factors (ATFs). Methods Mol Biol 649:163-182.
4. Blake DJ, Weir A, Newey SE, Davies KE. 2002. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82:291-329.
5. Blancafort P, Jin J, Frye S. 2013. Writing and rewriting the epigenetic code of cancer cells: From engineered proteins to small molecules. Mol Pharmacol 83:563-576.
6. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther 21:704-712.
7. Carter BJ. 2004. Adeno-associated virus and the development of adeno-associated virus vectors: A historical perspective. Mol Ther 10:981-989.
8. Carter BJ. 2005. Adeno-associated virus vectors in clinical trials. Hum Gene Ther 16:541-550.
9. Corbi N, Libri V, Fanciulli M, Tinsley JM, Davies KE, Passananti C. 2000. The artificial zinc finger coding gene 'Jazz' binds the utrophin promoter and activates transcription. Gene Ther 7:1076-1083.
10. Dennis CL, Tinsley JM, Deconinck AE, Davies KE. 1996. Molecular and functional analysis of the utrophin promoter. Nucleic Acids Res 24:1646-1652.
11. Desantis A, Onori A, Di Certo MG, Mattei E, Fanciulli M, Passananti C, Corbi N. 2009. Novel activation domain derived from Che-1 cofactor coupled with the artificial protein Jazz drives utrophin upregulation. Neuromuscul Disord 19:158-162.
12. Di Certo MG, Corbi N, Strimpakos G, Onori A, Luvisetto S, Severini C, Guglielmotti A, Batassa EM, Pisani C, Floridi A, Benassi B, Fanciulli M, Magrelli A, Mattei E, Passananti C. 2010. The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. Hum Mol Genet 19:752-760.
13. Fairclough RJ, Wood MJ, Davies KE. 2013. Therapy for Duchenne muscular dystrophy: Renewed optimism from genetic approaches. Nat Rev Genet 14:373-378.
14. Flotte TR, Conlon TJ, Mueller C. 2011. Preclinical study design for rAAV. Methods Mol Biol 807:317-337.
15. Gordon BS, Delgado Díaz DC, Kostek MC. 2013. Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy. Clin Nutr 32:104-111.
16. Goyenvalle A, Seto JT, Davies KE, Chamberlain J. 2011. Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20:R69-R78.
17. Grieger JC, Samulski RJ. 2012. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 507:229-254.
18. Gruntman AM, Bish LT, Mueller C, Sweeney HL, Flotte TR, Gao G. 2013. Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol 14:Unit 14D.3.
19. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. 2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet 369:2097-2105.
20. Klug A. 2010. The discovery of zinc fingers and their development for practical applications in gene regulation and genome manipulation. Q Rev Biophys 43:1-21.
21. Konieczny P, Swiderski K, Chamberlain JS. 2013. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 47:649-663.
22. Kwon I, Schaffer DV. 2008. Designer gene delivery vectors: Molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 25:489-499.
23. Lu Y, Tian C, Danialou G, Gilbert R, Petrof BJ, Karpati G, Nalbantoglu J. 2008. Targeting artificial transcription factors to the utrophin A promoter: Effects on dystrophic pathology and muscle function. J Biol Chem 283:34720-34727.
24. Mattei E, Corbi N, Di Certo MG, Strimpakos G, Severini C, Onori A, Desantis A, Libri V, Buontempo S, Floridi A, Fanciulli M, Baban D, Davies KE, Passananti C. 2007. Utrophin up-regulation by an artificial transcription factor in transgenic mice. PLoS One 2:e774.
25. Mayginnes JP, Reed SE, Berg HG, Staley EM, Pintel DJ, Tullis GE. 2006. Quantitation of encapsidated recombinant adeno-associated virus DNA in crude cell lysates and tissue culture medium by quantitative, real-time PCR. J Virol Methods 137:193-204.
26. McNally EM, Pytel P. 2007. Muscle diseases: The muscular dystrophies. Annu Rev Pathol 2:87-109.
27. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR. 2010. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68:629-638.
28. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark KR. 2012. Gene therapy for muscular dystrophy: Lessons learned and path forward. Neurosci Lett 527:90-99.
29. Miura P, Jasmin BJ. 2006. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: How close are we?. Trends Mol Med 12:122-129.
30. Moorwood C, Khurana TS. 2013. Duchenne muscular dystrophy drug discovery-The application of utrophin promoter activation screening. Expert Opin Drug Discov 8:569-581.
31. Mueller C, Flotte TR. 2008. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15:858-863.
32. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365:2357-2365.
33. Nigro G, Comi LI, Politano L, Bain RJ. 1990. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271-277.
34. Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. 2008. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 16:1539-1545.
35. Onori A, Desantis A, Buontempo S, Di Certo MG, Fanciulli M, Salvatori L, Passananti C, Corbi N. 2007. The artificial 4-zinc-finger protein Bagly binds human utrophin promoter A at the endogenous chromosomal site and activates transcription. Biochem Cell Biol 85:358-365.
36. Onori A, Pisani C, Strimpakos G, Monaco L, Mattei E, Passananti C, Corbi N. 2013. UtroUp is a novel six zinc finger artificial transcription factor that recognises 18 base pairs of the utrophin promoter and efficiently drives utrophin upregulation. BMC Mol Biol 14:3.
37. Passananti C, Corbi N, Onori A, Di Certo MG, Mattei E. 2010. Transgenic mice expressing an artificial zinc finger regulator targeting an endogenous gene. Methods Mol Biol 649:183-206.
38. Perkins KJ, Basu U, Budak MT, Ketterer C, Baby SM, Lozynska O, Lunde JA, Jasmin BJ, Rubinstein NA, Khurana TS. 2007. Ets-2 repressor factor silences extrasynaptic utrophin by N-box mediated repression in skeletal muscle. Mol Biol Cell 18:2864-2872.
39. Rodino-Klapac LR, Montgomery CL, Bremer WG, Shontz KM, Malik V, Davis N, Sprinkle S, Campbell KJ, Sahenk Z, Clark KR, Walker CM, Mendell JR, Chicoine LG. 2010. Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol Ther 18:109-117.
40. Sera T. 2009. Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliv Rev 61:513-526.
41. Tinsley JM, Fairclough RJ, Storer R, Wilkes FJ, Potter AC, Squire SE, Powell DS, Cozzoli A, Capogrosso RF, Lambert A, Wilson FX, Wren SP, De Luca A, Davies KE. 2011. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE 6:e19189.
42. Vandenberghe LH, Auricchio A. 2012. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther 19:162-168.
43. Veal EA, Jackson MJ. 1998. C-myc is expressed in mouse skeletal muscle nuclei during post-natal maturation. Int J Biochem Cell Biol 30:811-821.
44. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X. 2005. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23:321-328.